Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre
In our real-world experience, anifrolumab achieved sustained remission after just 3 months of treatment and a significant reduction in disease activity in most patients. These data suggest that SLE patients with active disease benefit from anifrolumab therapy regardless of prior therapies or disease duration.
Authors
- Arndt Weinmann (ORCID: https://orcid.org/0000-0003-1198-1716)
- Simone Cosima Boedecker-Lips (ORCID: https://orcid.org/0000-0002-7029-2622)
- Paul Claßen (ORCID: https://orcid.org/0000-0002-9410-0525)
- Matthias Plath
- Myriam Meineck (ORCID: https://orcid.org/0000-0002-3243-2540)
- Vanessa Tomalla
- Sabrina Saurin (ORCID: https://orcid.org/0000-0003-0222-2435)
- Daniel Kraus (ORCID: https://orcid.org/0000-0002-6351-3706)
- Marco Stortz (ORCID: https://orcid.org/0000-0002-3838-2150)
- Julia Weinmann‐Menke (ORCID: https://orcid.org/0000-0001-7344-8381)
- Andreas Kommer (ORCID: https://orcid.org/0009-0000-4444-164X)
- Janine Riepl
Institutions
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.55563/clinexprheumatol/728zl6
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00